RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Go back to RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial| RITE AID CORPORATION (NYSE: RAD) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $8.30 | |||
| Open | $11.16 | 52 Week Low | $6.33 | |||
| Day High | $0.65 | P/E | 1.91 | |||
| Day Low | $0.65 | EPS | $0.34 | |||
| Volume | 63,391 | |||||
| (NASDAQ: RADX) | Delayed: 2.29 -0.21 (8.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.50 | 52 Week High | $ | |||
| Open | $2.45 | 52 Week Low | $ | |||
| Day High | $2.45 | P/E | N/A | |||
| Day Low | $2.23 | EPS | $ | |||
| Volume | 88,943 | |||||
